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Malignancy in struma ovarii is a rare form of ovarian germ cell tumour. Because of its rarity, the diagnosis and management of the
tumour have not been clearly deﬁned. We present a case of 67- year-old female with papillary carcinoma arising in struma ovarii
and review the literature on malignancy in struma ovarii cases, focusing on management of these cases.
1.Introduction
15%–20% of ovarian tumours are teratoma. Struma ovarii is
diagnosed when thyroid tissue is the predominant element
(>50%) [1]. 5%–10% of these tumours are malignant,
with papillary carcinoma and follicular carcinoma being the
most common [1–3]. The percentage of papillary thyroid
carcinoma within malignant struma ovarii is 70%, 44%
of the tumours being classical type and 26% follicular
variant of papillary thyroid carcinoma [4]. Recently, a new
entity of follicular carcinoma, highly diﬀerentiated follicular
carcinoma of ovarian origin (HDFCO), characterized by
extraovarian dissemination of thyroid elements and histo-
logical resemblance to nonneoplastic thyroid tissue has been
described [5]. Due to the rarity of the disease, its treatment
is not uniform. Here we present a rare case of struma
ovarii with papillary thyroid carcinoma, and we review the
management and treatment option of this rare tumour.
2.Casereport
A 67-year-old female was admitted with abdominal dis-
tension and rapidly developing ascites. Ultrasound exam-
ination and CT scan of the abdomen and pelvis showed
extensive abdominopelvic ascites of unknown cause. No
intra-abdominal mass or pelvic abnormality was detected.
Tumour marker CA125 was raised, 2000KU/l (normal—less
than 35KU/l) but serum CEA levels were within normal
limits. Clinically, ovarian cancer was suspected, however
paracentesis demonstrated benign peritoneal eﬀusion. A
transvaginal scan showed solid/cystic mass in the pouch
of douglas 8×6×4cm. She underwent laparotomy which
showed copious amount of benign ascitic ﬂuid and a
left ovarian mass. The possibility of a dermoid cyst was
considered. A total abdominal hysterectomy with bilateral
salpingo-oopherectomy was performed along with omental
biopsy and peritoneal washing.
On gross pathological examination, there was a left ovar-
ian mass measuring 10×7×3.5cm. The external surface of
the cyst was mainly smooth with a small area of yellow/green
discolouration. Cut section of the cyst showed haemorrhagic
solid mass. Histology of the ovarian tumour showed thyroid
tissue characteristic of struma ovarii (Figure 1). However,
the thyroid tissue showed focal worrying features in the
form of small and large papillae (Figures 2 and 3) lined by
cells showing optically clear nuclei with thickened nuclear
membrane and overlapping nuclei (Figure 4). Scattered
psammoma bodies were also seen (Figure 5) .T h ec a s ew a s
sent for second opinion. The ﬁnal report conﬁrmed it to
be a struma ovarii with thyroid tissue showing neoplastic
transformation into classical papillary thyroid carcinoma.
The exact proportion and size of the carcinoma was
diﬃcult to estimate due to the smooth blending of the
benign and malignant components. However, the overall
malignant component was small measuring approximately
5mm. Immunohistochemistry and molecular studies were
not performed at our centre or by the histopathologist
providingsecondopinionasthefeatureswereunequivocalof2 Pathology Research International
Figure 1: Low-magniﬁcation view of benign thyroid tissue in the
ovary.
Figure 2: Areas with benign follicles as well as malignant papillary
architecture.
classical papillary thyroid carcinoma. The uterus, right ovary
and the Fallopian tubes were unremarkable. The peritoneal
washing and omental biopsy were negative for malignancy.
Postoperative thyroid function test was within normal limits.
Clinically there was no evidence of metastasis. The patient
was staged as FIGO stage Ia malignant struma ovarii and no
other adjuvant treatment was given. It was decided to keep
her on follow-up for the next ﬁve years. Presently, after a two
year follow-up, she is well with no evidence of recurrence.
3. Discussion
Struma ovarii is a rare and highly specialized form of
mature teratoma constituting 5% of all teratomas. The age
of presentation of malignancy in struma ovarii is usually in
t h e5 t hd e c a d eo fl i f e[ 1, 4] .C A1 2 5m a yb er a i s e da ss e e ni n
germ cell tumours. Ascites has been reported in 17% cases,
but the ﬂuid rarely contains tumour cells [4, 6].
A preoperative diagnosis of struma ovarii can be sus-
pected in cases with hyperthyroidism, but this is seen only in
5%–8% cases [4]. On radiology, the possibility can be raised
when a solid and cystic teratoma-like ovarian tumour shows
a well-vascularized solid component on colour Doppler
ultrasound, especially when a strongly enhancing solid
Figure 3: Papillary architecture with ﬁbrovascular core.
Figure 4: Areas with optically clear nuclei, thickened nuclear mem-
brane, and overlapping nuclei representing papillary carcinoma.
component is found in a multilocular tumour of the ovary
on computed tomography or MRI [7].
Macroscopically, the tumor is typically brown or green-
brown, predominantly solid and gelatinous. The thyroid
nature of this lesion has been conﬁrmed with biologic
and immunohistochemical studies [8]. Struma ovarii may
demonstrate all the pathologic patterns that are seen in
the thyroid gland including malignancy. The diagnosis of
thyroid-type carcinoma arising in struma ovarii largely
depends on the recognition of its characteristic microscopic
features with hematoxylin eosin-stained sections. The cri-
teria for malignancy was reviewed by Devaney et al. and
features is similar to that seen in thyroid, such as ground-
glass overlapping nuclei, nuclear grooves, and papillary
architectureforpapillarythyroidcarcinomainstrumaovarii.
Lesions showing hyperplastic type papillary formations but
lacking nuclear features have been diagnosed as proliferative
struma [1]. Lesions with nuclear features of papillary thyroid
carcinoma but lacking papillary architecture represent fol-
licular variant of papillary thyroid carcinoma (FVPTC). The
diagnosis of well-diﬀerentiated thyroid type follicular carci-
noma is more diﬃcult. Capsular invasion is an important
criterion of malignancy in follicular carcinoma, but there
is usually no capsule in the corresponding ovarian lesion.Pathology Research International 3
Figure 5: Areas with papillary structures and psamomma bodies.
Therefore,theidentiﬁcationofinvasionintothesurrounding
ovarian tissue, vascular invasion, or metastasis is employed
as evidence of malignancy [3]. The less diﬀerentiated forms
show signiﬁcant architectural abnormalities, nuclear atypia,
and mitotic activity. Immunohistochemical markers have
been suggested to help in the distinction between benign
thyroid tissue and papillary carcinoma of the thyroid,
Cytokeratin 19, HBME-1, and galectin-3 have been reported
to be valuable for this purpose [9, 10]. Roth and Karseladze
have recently suggested the term highly diﬀerentiated fol-
licular carcinoma of ovarian origin (HDFCO) for tumours
resembling nonneoplastic thyroid tissue in both the ovary
and sites of dissemination and proposed this term for
peritoneal strumosis cases. Because of the benign histologic
appearance of HDFCO, this form of follicular carcinoma
cannot be diagnosed until the neoplasm spreads beyond the
ovary [5].
Thyroid type carcinoma can also be seen in a mature
cystic teratoma or can be a component of strumal car-
cinoid. Strumal carcinoid is a form of ovarian teratoma
characterized by a mixture of thyroid tissue and carcinoid.
Immunohistochemistry using TTF-1 (thyroid transcription
factor 1), thyroglobulin, and neuroendocrine markers, such
as chromogranin or synaptophysin may assist in the diagno-
sis [3]. The cases of strumal carcinoid with a component of
thyroid-type carcinoma should be diagnosed as thyroid-type
carcinoma to ensure patients receive optimal follow-up and
therapy [11].
Malignancy arising in struma ovarii may mimic other
primary ovarian tumors, such as granulosa cell tumor,
Brenner tumor, papillary serous cystadenoma or cystade-
nocarcinoma. Granulosa tumor or Brenner tumor can be
a component of mature cystic teratoma and may have a
microfollicular or pseudotubular appearance with grooved
nuclei,whichmaysimulatefollicularcarcinomaorfollicular-
variant papillary thyroid carcinoma. The papillary appear-
ance and the presence of psammoma bodies in ovarian
papillary serous cystadenoma or cystadenocarcinoma may
mimic thyroid-type papillary carcinoma. In such cases
diagnosis can be made by the cytologic features of the
neoplastic cells, the presence of typical thyroid follicles
and immunohistochemistry such as thyroglobulin, TTF-1,
inhibin, WT1 (Wilms tumor 1), and CA 125 will help
diﬀerentiate these ovarian primary tumors from thyroid-
type carcinoma [3, 11, 12].
Molecular analysis has revealed that approximately 70%
of all follicular cell–derived thyroid carcinomas present
with activating mutations of BRAF (v-raf murine sarcoma
viral oncogene homolog B1), RAS, RET (rearranged during
transfection) and NTRK1 (neurotrophic tyrosine kinase
receptor 1) [13–15]. BRAF mutations are common in
papillary thyroid carcinoma and are seen in two-thirds of
malignant struma ovarii with papillary features as described
by Schmidt et al. BRAF mutations included V600E, K601E,
and TV599-600M [16]. Flavin et al. described a case of
classical papillary thyroid carcinoma arising in a struma
ovarii with heterozygous for BRAF T1799A mutation and
no ret/ PTC-1 or ret/PTC-3 rearrangements [17]. Kondo
et al. reviewed the pathogenetic mechanisms of thyroid
follicular cell neoplasia and found mutations of BRAF
(29%–69%), RET (13%–43%), and RAS (0%–21%) are
most commonly seen in adult papillary thyroid carcinoma;
RET rearrangements are more prevalent in adult tumors
associated with previous radiation exposure [14]. Celestino
et al. reported a case of follicular variant of papillary thyroid
carcinoma in a struma ovarii with NRAS mutation (Q61R)
and a PAX8-PPARc rearrangement which ﬁtted well with
the similar results seen in cervical counterpart [18]a n d
Coyne and Nikiforov reported HRAS codon 61 mutation in
a case of follicular variant of papillary thyroid carcinoma in
as t r u m ao v a r i i[ 19]. Papillary carcinomas harboring RAS
mutation almost always have the follicular variant histology.
Boutross-Tadrossetal.examined10casesoffollicularvariant
papillary thyroid carcinoma in struma ovarii and 3 cases of
benign struma ovarii and found all of the carcinomas were
diﬀusely positive for CK19 (cytokeratin 19), 8 were positive
for HMBE-1 (hector battifora mesothelial cell 1), and 7
exhibited RET/PTC rearrangement (ret/PTC-1 and ret/PTC-
3 rearrangements). Mutational analysis for BRAF identiﬁed
no V600E mutations. All 3 benign struma ovarii were
negative for CK19, HBME-1, and RET/PTC rearrangement
[20]. These molecular ﬁndings suggest that thyroid-type
carcinoma in struma ovarii are similar histologically and
genetically to cervical thyroid carcinoma.
Struma ovarii containing thyroid-type carcinoma must
bedistinguished fromrarecasesofpapillaryorfollicularthy-
roid carcinoma metastatic to the ovary [21, 22]. Metastasis
to the ovary from primary thyroid carcinoma can be ruled
out by clinical thyroid examination and ultrasonography.
In these cases, the ovarian masses are bilateral and have no
teratomatous features [23].
Metastasis is uncommon in patients with malignant
struma ovarii, seen in 5% to 23% cases [4]. The potential of
recurrenceandmetastasiswasconsideredlowintheprevious
literatures [1]. However, the recent literatures suggest a
higher rate of recurrence [4, 6, 24]. Roth et al. [25]r e v i e w e d
their own cases as well as literature cases and described that
a typical follicular carcinoma is more likely to metastasize to
the lung, liver, and central nervous system; whereas papillary
carcinoma involve the abdominal cavity and lymph nodes
and occasionally the liver [25].4 Pathology Research International
The management of cases of struma ovarii with thyroid
type malignancy is based on case reports and small cases
series review. Devaneyet al. studied 54 casesof struma which
were subdivided into “proliferative” struma (41 cases) and
“malignant” struma (13 cases). 11 of the 13 were papillary
carcinomas of thyroid type, whereas 2 were follicular carci-
noma. None of the patients received adjuvant therapy. On
follow-up examination (mean follow-up interval 7.3 years),
noneofthepatientshadclinicalevidenceofrecurrentdisease
[1].
DeSimone et al. reviewed the literature on malignancy
in struma ovarii in a series of 24 patients. 16 patients were
followed conservatively, while 8 received varied additional
therapy (4 cases received I131). There were 8 cases of
recurrences which occurred in the conservatively managed
patients. I131 for recurrent disease provided an initial com-
pleteresponsein7women.Therefore,theysuggesttreatment
with thyroidectomy and I131 as the ﬁrst line of management
for malignant struma ovarii [6].
Surgical removal of the ovarian mass remains the main
treatment; however the management after initial surgery is
still controversial. Mattucci et al. suggest the management
of malignancy in struma ovarii should be the same as for
carcinoma of the thyroid, so after surgical removing of ovar-
ian neoplasm, they recommend thyroidectomy, radiotherapy
with 131I, and levothyroxine suppressive therapy [26].
Makani et al. reviewed all reported cases till 2004, a total
of 39 cases. They found metastasis in nine cases (23%) and
recurrence in six cases (15%). The average time to detection
of recurrence was four years [4]. They recommend follow-up
with surveillance of thyroglobulin levels for at least 10 years.
Thyroglobulin is a sensitive marker for monitoring cases of
struma ovarii, both benign and malignant, during treatment
and follow-up [2, 27, 28].
Ozata et al. described that 98% of thyroid cancer patients
with a serum thyroglobulin less than10ng/ml were clinically
free of disease [29]. Therefore, some authors suggest initi-
ating 131I therapy in patients with serum thyroglobulin of
>10ng/mL. For detecting recurrence, serum thyroglobulin
and serial 131I diagnostic whole body scanning is suggested.
In patients with elevated thyroglobulin who do not respond
to radioactive iodine, PET/CT is considered most useful in
thedetectionandmanagementofrecurrentpapillarythyroid
cancer [30].
Some authors have advocated the management of malig-
nancy in struma as other germ cell tumours [31] while
others have proposed that it should be treated like its thyroid
counterpart. Thelatteristhe favouredapproachin therecent
literatures [32–34].
The standard treatment of a patient with thyroid malig-
nancy in struma ovarii is total abdominal hysterectomy,
bilateralsalpingo-oophorectomy,andcompletesurgicalstag-
ing, including peritoneal washings for cytology, pelvic and
para-aortic lymph node sampling, and omentectomy [4, 28].
In cases with residual malignant disease after surgery, a total
thyroidectomy and radioablation with 131Ii sr e c o m m e n d e d
[6, 35]. Chemotherapy and external beam radiotherapy and
thyroid suppression have been used for the treatment of
recurrent or metastatic disease [26].
Yassa et al. suggest a risk stratiﬁcation of malignancy
in struma ovarii patients; small focus of thyroid carcinoma
conﬁned to the struma ovarii measuring less than 2cm,
with no worrisome histologic features to be considered as
low risk. Patients with larger carcinomas, disease outside
the struma ovarii, or more aggressive histologic features are
considered as high risk. For younger patients with malignant
struma ovarii who wish to preserve fertility, oophorectomy
is appropriate surgery if there is no extra-ovarian disease.
For patients with low risk of persistent or recurrent thyroid
carcinoma, thyroxine therapy, pelvic imaging, and periodic
measurements of serum thyroglobulin are recommended
and in patients with a higher risk of recurrence based on the
pathology of the carcinoma, near-total thyroidectomy with
radioactive iodine ablation is indicated [24].
Janszen et al. recommend that the best option for
patients with malignant struma ovarii larger than one cm is
total thyroidectomy followed by 131I ablation therapy. After
131I ablation any detectable serum thyroglobulin points to
persistent or recurrent disease [32].
The prognosis of thyroid-type carcinoma arising in
struma ovarii is diﬃcult to estimate due to its rarity and the
absence of consensus in treatment. Roth et al. reviewed the
literatureandrevealed14%withtypicalfollicularcarcinoma,
7% with papillary carcinoma, 100% with undiﬀerentiated
(anaplastic) carcinoma, and 0% with HDFCO died of
neoplasm [25]. Robboy et al. reviewed 88 cases of malignant
struma ovarii and they found that even when clinically
malignant, the tumour is often associated with long survival,
as evidenced by an 84% 25-year survival. They describe that
unless obviously poorly diﬀerentiated, no single histologic
or clinical feature reliably predicts which tumors will be
biologically malignant, although dense ﬁbrous adhesions
and larger strumal size, especially over 12cm, are suggestive
of tumours that will have spread at the time of operation or
are likely to recur [12].
In our case the focus of papillary thyroid carcinoma
was small and the postoperative thyroid function test was
normal. In the multidisciplinary meeting, it was decided that
becausethechanceofrecurrencewaslow,thepatientshallbe
followed up.
In conclusion, the treatment modalities for malignancy
in struma ovarii depend on the stage of the disease. The
initial surgery options include unilateral oophorectomy;
total hysterectomy and bilateral salpingo-oophorectomy or
total hysterectomy, bilateral salpingooophorectomy with
omentectomyandlymphnodesampling.Theadjuvanttreat-
ment options include thyroxine, near-total thyroidectomy
with radioactive iodine ablation or no adjuvant treatment.
Long-term follow-up is recommended in all cases.
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